- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02657252
Polidocanol Versus Glucose Treatment of Telangiectasia Trial (PG3T)
Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background. The prevalence of chronic venous disease is high in the general population, mainly in young women, and in milder cases the usual complaint is aesthetic. Various techniques are used for treatment of mild varicose disease, including surgical treatment, laser ablation and sclerotherapy. Telangiectasis are those with less than 1 mm diameter, reddish and important contribution to the aesthetic damage, and sometimes they are related to local pain. There is no consensus in the literature about the effectiveness of treatment with sclerotherapy, despite of being an usual procedure with different chemicals.
Methods and design. One hundred lower limbs of healthy women between 18 and 65 years will be triple blind randomized to receive treatment with polidocanol 0.2% diluted in 70% hypertonic glucose versus 75% hypertonic glucose for sclerotherapy treatment of telangiectasis. The patients will be examined and clinically classified. It will be included patients with telangiectasis sited at out's thigh, and only one extremity will be included per patient. The patients with varicose disease CEAP 2 or more will not be included. The treatment will be carried out in only one session and the medication volume not exceeding 5 ml. Clinical follow-up protocols will be filled on regular visits on days 0 - 7 - 60 concomitantly with photograph documentation. Supplementary examination for venous mapping with ultrasound pretreatment is performed for all patients.
Discussion. This prospective controlled double-blind randomized trial aims to verify and compare the efficacy and safety for sclerotherapy treatment of telangiectasis of the lower limbs. The results may help physicians to choose the best sclerotherapy treatment for telangiectasis.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
São Paulo
-
Botucatu, São Paulo, Brazil, 18618687
- Vascular Lab
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- females
- with telangiectasis on thigh side
- clinical classification of chronic venous disease C1(mild venous disease),
- minimum age of 18 year-old and maximum age 65 year-old
- agreement with the study
- signing the free and informed consent ( IC)
- not use anticoagulant drugs .
Exclusion Criteria:
- male
- varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)
- restrict mobility
- arterial insufficiency
- be allergic to any substance that may be related to the study drugs
- any cause of dermatitis on application site
- don´t be free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism
- pregnancy
- previous deep vein thrombosis (DVT)
- family history of DVT
- thrombophilia
- do not agree with the search terms
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Glucose
An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml.
Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
|
Sclerotherapy of telangiectasis in one lower limb.
Other Names:
|
Active Comparator: Polidocanol with Glucose
An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml.
Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
|
Sclerotherapy of telangiectasis in one lower limb.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Extent of Telangiectasias
Time Frame: 2 months
|
Efficiency in promoting the disappearance of the treated telangiectasias, making the comparison between the initial measurements in centimeters and after two months, then comparing the treatment between the two treatments
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skin Hyperpigmentation
Time Frame: 2 months
|
Observed after two months of treatment the occurrence of hyperpigmentation stains in the treated areas.
Measuring in centimeters those stains and compare the two treatments together.
|
2 months
|
Number of Participants With Deep Venous Thrombosis (DVT)
Time Frame: 1 week
|
Observe after one week of treatment occurred if clinical signs and symptoms of deep vein thrombosis (DVT) and perform duplex ultrasound for confirmation.
Compare the results between the two groups to establish a security policy.
|
1 week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matheus Bertanha, Dr, Botucatu School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPECLIN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Varicose Veins
-
EMSWithdrawn
-
EMSWithdrawn
-
I-VASC S.r.lRecruiting
-
Acotec Scientific Co., LtdZhejiang UniversityCompletedVaricose Veins of Lower LimbChina
-
Beijing Tsinghua Chang Gung HospitalActive, not recruiting
-
Oulu University HospitalCompletedVaricose Veins | Varicose Veins of Lower LimbFinland
-
Kahramanmaras Sutcu Imam UniversityUnknown
-
Helsinki University Central HospitalActive, not recruiting
-
The Fourth Affiliated Hospital of Zhejiang University...RecruitingVaricose Veins of Lower LimbChina
-
Worcestershire Acute Hospitals NHS TrustCompletedVaricose Veins of Lower LimbUnited Kingdom
Clinical Trials on Glucose
-
University of Texas Southwestern Medical CenterCompletedSarcoma | Neuroblastoma | Pediatric CancerUnited States
-
Children's Mercy Hospital Kansas CityWithdrawnType 1 DiabetesUnited States
-
University of Massachusetts, WorcesterNot yet recruitingPregnancy, High Risk | Type 2 Diabetes Treated With InsulinUnited States
-
Glostrup University Hospital, CopenhagenUnknown
-
Makassed General HospitalCompleted
-
US Department of Veterans AffairsEmory UniversityCompletedType 2 Diabetes Mellitus | Prediabetic StateUnited States
-
NestléCompletedHealthyNew Zealand
-
Unilever R&DLeiden University Medical CenterCompleted